SCHEMBL1767528

SCHEMBL1767528

O=C(NCc1ccccc1)c1ccnc(N2CCN(Cc3ccc4nonc4c3)C2=O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.55
▸ ADORA2A P29274 1/20 0.55
▸ ADORA2B P29275 1/20 0.55
▸ ADORA1 P30542 1/20 0.55
▸ SCD O00767 8/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ MAPT P10636 4/20 0.41
▸ THRB P10828 1/20 0.41
▸ HDAC1 Q13547 2/20 0.41
▸ TP53 P04637 1/20 0.40
▸ HPGD P15428 2/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ GFER P55789 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1767578 0.88 SCD (0.49) SCDSMN1; SMN2HTTLMNAMAPT
SCHEMBL1568693 0.85 SCD (0.62) SCDSMN1; SMN2HTTLMNAMAPT
SCHEMBL1767355 0.85 SCD (0.62) SCDSMN1; SMN2HTTLMNAMAPT
SCHEMBL1767626 0.81 SCD (0.56) SCDSMN1; SMN2LMNAMAPTTHRB
SCHEMBL17263333 0.79 SCD (0.53) SCDSMN1; SMN2LMNAMAPTTHRB
SCHEMBL1767391 0.79 SCD (0.52) SCDSMN1; SMN2HTTLMNAALDH1A1
SCHEMBL1767520 0.79 SCD (0.50) SCDSMN1; SMN2LMNAMAPTTHRB
SCHEMBL1767544 0.78 L3MBTL1 (0.54) SCDSMN1; SMN2MAPTTHRBHDAC1
SCHEMBL1767388 0.78 L3MBTL1 (0.54) SCDSMN1; SMN2MAPTTHRBHDAC1
SCHEMBL17263322 0.77 SCD (0.58) SCDLMNAMAPTHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160289191-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2016-10-06 — — US claimed
US-20110105530-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-05-05 — — US claimed
US-20160289191-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2016-10-06 — — US disclosed
US-20160289191-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2016-10-06 — — US disclosed
US-20160289191-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2016-10-06 — — US disclosed
US-9187426-B2 Organic compounds NOVARTIS AG (CH) 2015-11-17 — — US disclosed
US-9187426-B2 Organic compounds NOVARTIS AG (CH) 2015-11-17 — — US disclosed
US-20110105530-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-05-05 — — US disclosed
US-20110105530-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-05-05 — — US disclosed
WO-2009156484-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105530-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 ADORA3 3071/4885ADORA2A 2729/4885ADORA2B 3554/4885
US-20160289191-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 ADORA3 3071/4885ADORA2A 2729/4885ADORA2B 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback